文献速递银屑病与炎症性皮肤病皮肤感染

银屑病及银屑病关节炎患者使用生物制剂和靶向合成DMARDs后乙肝和丙肝再激活风险的比较:一项15年多中心队列研究

Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study.
PubMed 文献 · J Am Acad Dermatol · 2025-09-17

该多中心队列研究纳入1525个符合条件的治疗周期(1343个HBV周期,182个HCV周期),评估银屑病及银屑病关节炎患者使用生物制剂和靶向合成DMARDs后HBV和HCV再激活的相对风险。结果显示HBV再激活143例(10.6%),HCV再激活18例(9.9%);TNF-α抑制剂风险最高,其次为IL-12/23i、IL-17i和IL-23i。HBsAg阳性、HBeAg阳性、合并免疫抑制剂及未预防性抗病毒与HBV再激活显著相关;较高基线病毒载量和TNF-α抑制剂与HCV再激活相关。

要点

  • TNF-α抑制剂再激活风险最高,IL-23i最低。
  • HBsAg或HBeAg阳性、合用免疫抑制剂、未抗病毒预防增加HBV再激活风险。
  • 高基线病毒载量和TNF-α抑制剂与HCV再激活相关。

核心结论

  • 在银屑病及银屑病关节炎患者中,不同靶向治疗的HBV和HCV再激活风险存在差异,选择治疗方案时应考虑此差异,尤其对具有病毒再激活危险因素的患者。

研究设计与样本

  • 多中心队列研究,筛选5527个治疗周期,纳入1525个符合条件的治疗周期(1343个HBV周期,182个HCV周期)。

主要发现

  • HBV再激活143例(10.6%),随访2104.5人年;HCV再激活18例(9.9%),随访271.2人年。
  • HBV和HCV再激活风险均为TNF-α抑制剂最高,其次为IL-12/23i、IL-17i和IL-23i。
  • HBsAg阳性、HBeAg阳性、合并使用免疫抑制剂及未预防性抗病毒与HBV再激活显著相关。
  • 较高基线病毒载量和TNF-α抑制剂与HCV再激活相关。

临床怎么用

  • 选择靶向治疗时需评估HBV和HCV再激活风险,对高危患者(如HBsAg阳性、HBeAg阳性、高病毒载量)优先选择风险较低的药物并考虑抗病毒预防。

局限性

  • 观察性设计且非随机治疗分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relative risks of HBV reactivation (HBVr) and HCV reactivation (HCVr) associated with different immunosuppressant agents in psoriasis and psoriatic arthritis are unknown. OBJECTIVE: We assessed the comparative risks of HBVr and HCVr for patients treated with biologics and targeted synthetic disease-modifying antirheumatic drugs. METHODS: We screened 5,527 treatment episodes (TEs) with available HBV and HCV serology data from 3197 patients who received biologics or targeted synthetic disease-modifying antirheumatic drugs; 1525 eligible TEs (1343 HBV TEs; 182 HCV TEs) were included. RESULTS: HBVr and HCVr occurred in 143 (10.6%) and 18 (9.9%) of TEs during 2104.5 and 271.2 person-years of follow-up, respectively. The risks of HBVr and HCVr were highest for tumor necrosis factor-α inhibitors, followed by interleukin-12/23 inhibitor (IL-12/23i), IL-17i, and IL-23i. Analysis revealed drug class (tumor necrosis factor-α inhibitors), hepatitis B surface antigen-positivity, hepatitis B e-antigen-positivity, concomitant use of immunosuppressants, and absence of antiviral prophylaxis were significantly associated with HBVr; a higher baseline viral load and drug class (tumor necrosis factor-α inhibitors) were associated with HCVr. LIMITATIONS: Observational design and nonrandom treatment allocation. CONCLUSIONS: The differential risks of HBVr and HCVr should be considered when selecting targeted therapies in psoriasis and psoriatic arthritis, particularly for patients with risk factors for viral reactivation.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Chiu HY, Hsu CC, Tsai TF, et al. Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: A 15-year multicenter cohort study. J Am Acad Dermatol. 2025. PMID: 40972765. doi:10.1016/j.jaad.2025.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。